Abstract
The blood-brain barrier (BBB) is a physiological regulator of transport of essential items from blood to brain for the maintenance of homeostasis of the central nervous system (CNS) within narrow limits. The BBB is also responsible for export of harmful or metabolic products from brain to blood to keep the CNS fluid microenvironment healthy. However, noxious insults to the brain caused by trauma, ischemia or environmental/chemical toxins alter the BBB function to small as well as large molecules e.g., proteins. When proteins enter the CNS fluid microenvironment, development of brain edema occurs due to altered osmotic balance between blood and brain. On the other hand, almost all neurodegenerative diseases and traumatic insults to the CNS and subsequent BBB dysfunction lead to edema formation and cell injury. To treat these brain disorders suitable drug therapy reaching their brain targets is needed. However, due to edema formation or only a focal disruption of the BBB e.g., around brain tumors, many drugs are unable to reach their CNS targets in sufficient quantity. This results in poor therapeutic outcome. Thus, new technology such as nanodelivery is needed for drugs to reach their CNS targets and be effective. In this review, use of nanowires as a possible novel tool to enhance drug delivery into the CNS in various disease models is discussed based on our investigations. These data show that nanowired delivery of drugs may have superior neuroprotective ability to treat several CNS diseases effectively indicating their role in future therapeutic strategies.
Keywords: Alzheimer disease, blood-brain barrier, brain edema, central nervous system injury, ischemic insult, nanowired drug delivery, neuroproetction, Parkinson disease, traumatic brain injury.
CNS & Neurological Disorders - Drug Targets
Title:Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
Volume: 15 Issue: 9
Author(s): Aruna Sharma, Preeti Menon, Dafin F. Muresanu, Asya Ozkizilcik, Z. Ryan Tian, José V. Lafuente and Hari S. Sharma
Affiliation:
Keywords: Alzheimer disease, blood-brain barrier, brain edema, central nervous system injury, ischemic insult, nanowired drug delivery, neuroproetction, Parkinson disease, traumatic brain injury.
Abstract: The blood-brain barrier (BBB) is a physiological regulator of transport of essential items from blood to brain for the maintenance of homeostasis of the central nervous system (CNS) within narrow limits. The BBB is also responsible for export of harmful or metabolic products from brain to blood to keep the CNS fluid microenvironment healthy. However, noxious insults to the brain caused by trauma, ischemia or environmental/chemical toxins alter the BBB function to small as well as large molecules e.g., proteins. When proteins enter the CNS fluid microenvironment, development of brain edema occurs due to altered osmotic balance between blood and brain. On the other hand, almost all neurodegenerative diseases and traumatic insults to the CNS and subsequent BBB dysfunction lead to edema formation and cell injury. To treat these brain disorders suitable drug therapy reaching their brain targets is needed. However, due to edema formation or only a focal disruption of the BBB e.g., around brain tumors, many drugs are unable to reach their CNS targets in sufficient quantity. This results in poor therapeutic outcome. Thus, new technology such as nanodelivery is needed for drugs to reach their CNS targets and be effective. In this review, use of nanowires as a possible novel tool to enhance drug delivery into the CNS in various disease models is discussed based on our investigations. These data show that nanowired delivery of drugs may have superior neuroprotective ability to treat several CNS diseases effectively indicating their role in future therapeutic strategies.
Export Options
About this article
Cite this article as:
Sharma Aruna, Menon Preeti, Muresanu F. Dafin, Ozkizilcik Asya, Tian Ryan Z., Lafuente V. José and Sharma S. Hari, Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair, CNS & Neurological Disorders - Drug Targets 2016; 15 (9) . https://dx.doi.org/10.2174/1871527315666160819123059
DOI https://dx.doi.org/10.2174/1871527315666160819123059 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits
CNS & Neurological Disorders - Drug Targets Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Targeting PPAR Isoforms Following CNS Injury
Current Drug Targets Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion
Combinatorial Chemistry & High Throughput Screening Neurohypophyseal Dysfunction During Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry The Crosstalk between Gut Inflammation and Gastrointestinal Disorders During Acute Pancreatitis
Current Pharmaceutical Design Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option
Current Topics in Medicinal Chemistry Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Surrogate Outcomes for Progression in the Initial Stages of Diabetic Retinopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Nociceptive and Anti-Inflammatory Effects of Stem Bark Extract of <i>Ficus Capensis</i> Thunb (Moraceae) by Bioactivity Fractionation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Cardiovascular Control After Spinal Cord Injury
Current Vascular Pharmacology Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science